Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

UPDATE: JMP Securities Initiates Coverage on Lpath on Potential of iSONEP and ASONEP


In a report published Tuesday, JMP Securities analyst John L. Newman initiated coverage on Lpath (NASDAQ: LPTN) with a Market Outperform rating and $14.00 price target.

In the report, JMP Securities noted, “We are initiating coverage on Lpath with a Market Outperform rating and establishing a $14 price target based on a probability-adjusted Net Present Value calculation. Lpath is developing two lipid-targeting antibodies, iSONEP for eye disease, and ASONEP for kidney cancer, with iSONEP holding under-appreciated value, in our view.”

Lpath closed on Monday at $4.81.

Latest Ratings for LPTN

Apr 2014Initiates Coverage onBuy
Nov 2013Initiates Coverage onBuy
Dec 2012Initiates Coverage onBuy

View More Analyst Ratings for LPTN
View the Latest Analyst Ratings

Posted-In: JMP Securities John L. NewmanAnalyst Color Initiation Analyst Ratings


Related Articles (LPTN)

View Comments and Join the Discussion!

Latest Ratings

FMCInitiates Coverage On82.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: JMP Securities Raises PT on NorthStar Realty Finance Corp. on Multiple Positive Factors

UPDATE: JMP Securities Initiates Coverage on BIND Therapeutics on Recipe for Significant Value Creation